Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Pascal R. Hammel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4630-4996; OpenAlex author ID A5067073528. Sources: ClinicalTrials.gov.

Their work

Papers
100 (first author 10, last author 21)
Trials
6 (principal investigator on 4)
Grants
0
Labs led
3
Collaborators
315
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: 1 trial · 2006: none · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: 2 papers · 2012: 5 papers · 2013: 4 papers · 2014: 2 papers, 1 trial · 2015: 10 papers · 2016: 6 papers · 2017: 4 papers · 2018: 6 papers, 1 trial · 2019: 10 papers · 2020: 11 papers, 1 trial · 2021: 9 papers · 2022: 6 papers · 2023: 9 papers · 2024: 2 papers · 2025: 7 papers · 2026: 7 papers

Papers 50 of 100

  1. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  4. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  5. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  6. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  7. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Last author DOI 10.64898/2026.06.18.26355998↗
  8. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. Co-author DOI 10.1002/jcsm.13595↗
  9. Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu. First author DOI 10.1016/j.annonc.2024.09.016↗
  10. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Last author DOI 10.1016/j.ctrv.2025.102973↗
  11. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  12. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  13. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  14. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  15. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.annonc.2024.06.010↗
  16. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  17. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply. Last author DOI 10.1001/jamaoncol.2022.7361↗
  18. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. Co-author DOI 10.1016/j.esmogo.2023.08.010↗
  19. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. Co-author DOI 10.1016/s2468-1253(23)00207-8↗
  20. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  21. Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in pat… Co-author DOI 10.1136/bmjopen-2022-069973↗
  22. Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221146132↗
  23. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Co-author DOI 10.1177/17588359231163776↗
  24. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Co-author DOI 10.1177/17588359231189127↗
  25. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Last author DOI 10.6004/jnccn.2023.7065↗
  26. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  27. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  28. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  29. Time interval from last visit to imaging diagnosis influences outcome in pancreatic adenocarcinoma: A regional population-based study on linked medico-administ… Co-author DOI 10.1177/17588359221113264↗
  30. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Last author DOI 10.1177/17588359221118019↗
  31. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… First author DOI 10.1200/jco.21.01604↗
  32. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  33. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
  34. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Co-author DOI 10.1016/j.clinre.2020.101607↗
  35. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2021.01.042↗
  36. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.05.006↗
  37. Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential dia… Last author DOI 10.1177/17588359211053412↗
  38. A novel event-free survival endpoint in locally advanced pancreatic cancer. Co-author DOI 10.1177/17588359211059586↗
  39. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  40. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. First author DOI 10.6004/jnccn.2021.7031↗
  41. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  42. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  43. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Last author DOI 10.1016/s2468-1253(19)30327-9↗
  44. PARP inhibition in treatment of pancreatic cancer. Co-author DOI 10.1080/14737140.2020.1820330↗
  45. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-0950↗
  46. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Co-author DOI 10.1177/1758835920937949↗
  47. Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. Last author DOI 10.1177/2050640620939788↗
  48. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Co-author DOI 10.1200/jco.19.01890↗
  49. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  50. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗

Trials 6

  1. Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. Principal investigator NCT04348045↗
  2. Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial Principal investigator NCT03400072↗
  3. Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer Principal investigator NCT02184663↗
  4. Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreati… Principal investigator NCT00634725↗
  5. Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Study chair NCT00303758↗
  6. Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer Study chair NCT00064207↗

Closest collaborators

The 25 strongest of 315 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 31 shared papers, 2013–2026 · strength 3.62
  2. Jean‐Baptiste Bachet · 34 shared papers, 2012–2026 · strength 3.46
  3. Cindy Neuzillet · 21 shared papers, 2011–2026 · strength 2.34
  4. Rémy Nicolle · 14 shared papers, 2021–2026 · strength 2.19
  5. Nelson Dusetti · 12 shared papers, 2021–2026 · strength 2.14
  6. Anthony Turpin · 13 shared papers, 2020–2026 · strength 2.13
  7. Louis de Mestier · 18 shared papers, 2015–2026 · strength 2.04
  8. Juan Iovanna · 11 shared papers, 2012–2026 · strength 1.81
  9. Vinciane Rebours · 16 shared papers, 2012–2026 · strength 1.80
  10. Thierry Conroy · 11 shared papers, 2012–2026 · strength 1.56
  11. Teresa Mercade Macarulla · 11 shared papers, 2014–2025 · strength 1.00
  12. James Biagi · 6 shared papers, 2018–2026 · strength 1.00
  13. Aurélien Lambert · 5 shared papers, 2024–2026 · strength 0.96
  14. Christophe Louvet · 15 shared papers, 2012–2026 · strength 0.96
  15. Magali Svrcek · 12 shared papers, 2012–2023 · strength 0.96
  16. Nicolas Alejandro Fraunhoffer · 4 shared papers, 2024–2026 · strength 0.92
  17. Marc Hilmi · 5 shared papers, 2020–2026 · strength 0.88
  18. Christophe Tournigand · 8 shared papers, 2015–2026 · strength 0.88
  19. Thierry André · 13 shared papers, 2012–2026 · strength 0.88
  20. Talia Golan · 6 shared papers, 2019–2023 · strength 0.85
  21. Déwi Vernerey · 6 shared papers, 2016–2026 · strength 0.82
  22. Olivier Bouché · 9 shared papers, 2011–2025 · strength 0.80
  23. Isabelle Trouilloud · 5 shared papers, 2021–2026 · strength 0.78
  24. Jean‐Luc Van Laethem · 12 shared papers, 2012–2025 · strength 0.77
  25. Eric Van Cutsem · 8 shared papers, 2018–2025 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.